Matthew J. D'Onofrio - 28 Feb 2025 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Role
Chief Executive Officer, Director
Signature
/s/ Matthew J. D'Onofrio
Issuer symbol
EVOK
Transactions as of
28 Feb 2025
Net transactions value
+$24,999
Form type
4
Filing time
03 Mar 2025, 16:30:04 UTC
Previous filing
29 Jan 2025
Next filing
24 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVOK Common Stock Award $24,999 +6,849 +347% $3.65 8,820 28 Feb 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c) and Rule 16b-3(d).